BIMI International Medical Inc. (BIMI)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 30.49 Million USD | 13.83% |
| 2021 | 26.79 Million USD | 64.28% |
| 2020 | 16.3 Million USD | -24.32% |
| 2019 | 21.54 Million USD | 64.93% |
| 2018 | 13.06 Million USD | -7.58% |
| 2017 | 14.13 Million USD | 33.21% |
| 2016 | 10.61 Million USD | -24.07% |
| 2015 | 13.97 Million USD | -17.65% |
| 2014 | 16.97 Million USD | 56.98% |
| 2013 | 10.81 Million USD | -16.95% |
| 2012 | 13.01 Million USD | -8.96% |
| 2011 | 14.3 Million USD | 83.85% |
| 2010 | 7.77 Million USD | 42.65% |
| 2009 | 5.45 Million USD | 117.7% |
| 2008 | 2.5 Million USD | 46.65% |
| 2007 | 1.7 Million USD | 36.43% |
| 2006 | 1.25 Million USD | 95.54% |
| 2005 | 640.16 Thousand USD | 18.04% |
| 2004 | 542.33 Thousand USD | 71.98% |
| 2003 | 315.35 Thousand USD | 74.2% |
| 2002 | 181.02 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q3 | 24.89 Million USD | 3.12% |
| 2023 Q1 | 27.65 Million USD | -9.32% |
| 2023 Q2 | 24.14 Million USD | -12.69% |
| 2022 Q3 | 22.79 Million USD | -11.73% |
| 2022 Q2 | 25.82 Million USD | 1.99% |
| 2022 FY | 30.49 Million USD | 13.83% |
| 2022 Q4 | 30.49 Million USD | 33.8% |
| 2022 Q1 | 25.31 Million USD | -5.5% |
| 2021 Q3 | 28.29 Million USD | -11.52% |
| 2021 FY | 26.79 Million USD | 64.28% |
| 2021 Q1 | 25.27 Million USD | 54.98% |
| 2021 Q2 | 31.97 Million USD | 26.51% |
| 2021 Q4 | 26.79 Million USD | -5.3% |
| 2020 Q3 | 20.16 Million USD | -12.94% |
| 2020 Q4 | 16.3 Million USD | -19.12% |
| 2020 Q2 | 23.16 Million USD | -31.67% |
| 2020 Q1 | 33.89 Million USD | 57.31% |
| 2020 FY | 16.3 Million USD | -24.32% |
| 2019 Q1 | 14.58 Million USD | 11.66% |
| 2019 FY | 21.54 Million USD | 64.93% |
| 2019 Q4 | 21.54 Million USD | 48.03% |
| 2019 Q3 | 14.55 Million USD | 0.96% |
| 2019 Q2 | 14.41 Million USD | -1.16% |
| 2018 Q1 | 13.3 Million USD | -5.88% |
| 2018 Q2 | 13.56 Million USD | 1.92% |
| 2018 FY | 13.06 Million USD | -7.58% |
| 2018 Q3 | 12.51 Million USD | -7.73% |
| 2018 Q4 | 13.06 Million USD | 4.42% |
| 2017 Q2 | 11.73 Million USD | 4.43% |
| 2017 Q1 | 11.24 Million USD | 5.93% |
| 2017 Q3 | 13.04 Million USD | 11.12% |
| 2017 Q4 | 14.13 Million USD | 8.37% |
| 2017 FY | 14.13 Million USD | 33.21% |
| 2016 Q1 | 11.39 Million USD | -18.49% |
| 2016 FY | 10.61 Million USD | -24.07% |
| 2016 Q2 | 11.24 Million USD | -1.31% |
| 2016 Q3 | 11.15 Million USD | -0.81% |
| 2016 Q4 | 10.61 Million USD | -4.84% |
| 2015 Q4 | 13.97 Million USD | 7.3% |
| 2015 Q3 | 13.02 Million USD | -9.52% |
| 2015 FY | 13.97 Million USD | -17.65% |
| 2015 Q2 | 14.39 Million USD | 1.81% |
| 2015 Q1 | 14.13 Million USD | -16.69% |
| 2014 Q2 | 12.3 Million USD | 9.5% |
| 2014 Q4 | 16.97 Million USD | 24.52% |
| 2014 Q1 | 11.23 Million USD | 3.92% |
| 2014 FY | 16.97 Million USD | 56.98% |
| 2014 Q3 | 13.62 Million USD | 10.79% |
| 2013 Q2 | 13.36 Million USD | 17.82% |
| 2013 Q3 | 11.66 Million USD | -12.76% |
| 2013 Q4 | 10.81 Million USD | -7.3% |
| 2013 FY | 10.81 Million USD | -16.95% |
| 2013 Q1 | 11.34 Million USD | -12.85% |
| 2012 Q1 | 14.29 Million USD | -0.06% |
| 2012 Q3 | 15.59 Million USD | 9.89% |
| 2012 Q2 | 14.19 Million USD | -0.68% |
| 2012 FY | 13.01 Million USD | -8.96% |
| 2012 Q4 | 13.01 Million USD | -16.54% |
| 2011 Q3 | 9.01 Million USD | -3.9% |
| 2011 FY | 14.3 Million USD | 83.85% |
| 2011 Q4 | 14.3 Million USD | 58.63% |
| 2011 Q2 | 9.38 Million USD | 19.6% |
| 2011 Q1 | 7.84 Million USD | 0.84% |
| 2010 Q3 | 5.07 Million USD | 0.8% |
| 2010 Q1 | 3.71 Million USD | -31.93% |
| 2010 Q4 | 7.77 Million USD | 53.13% |
| 2010 FY | 7.77 Million USD | 42.65% |
| 2010 Q2 | 5.03 Million USD | 35.75% |
| 2009 FY | 5.45 Million USD | 117.7% |
| 2009 Q2 | 4.23 Million USD | 11.96% |
| 2009 Q3 | 5.83 Million USD | 37.74% |
| 2009 Q1 | 3.78 Million USD | 51.04% |
| 2009 Q4 | 5.45 Million USD | -6.54% |
| 2008 Q2 | 1.59 Million USD | -7.28% |
| 2008 Q4 | 2.5 Million USD | -11.91% |
| 2008 FY | 2.5 Million USD | 46.65% |
| 2008 Q3 | 2.84 Million USD | 78.12% |
| 2008 Q1 | 1.72 Million USD | 0.81% |
| 2007 Q1 | 1.13 Million USD | -9.24% |
| 2007 Q4 | 1.7 Million USD | 74.89% |
| 2007 Q3 | 976.47 Thousand USD | -27.24% |
| 2007 FY | 1.7 Million USD | 36.43% |
| 2007 Q2 | 1.34 Million USD | 18.13% |
| 2006 Q1 | 312.14 Thousand USD | -51.24% |
| 2006 Q2 | 382.35 Thousand USD | 22.49% |
| 2006 Q4 | 1.25 Million USD | 3797.0% |
| 2006 Q3 | 32.12 Thousand USD | -91.6% |
| 2006 FY | 1.25 Million USD | 95.54% |
| 2005 Q1 | 537.03 Thousand USD | -0.98% |
| 2005 Q4 | 640.16 Thousand USD | 4.38% |
| 2005 Q2 | 558.97 Thousand USD | 4.09% |
| 2005 Q3 | 613.28 Thousand USD | 9.72% |
| 2005 FY | 640.16 Thousand USD | 18.04% |
| 2004 Q3 | 765.42 Thousand USD | 97.51% |
| 2004 FY | 542.33 Thousand USD | 71.98% |
| 2004 Q2 | 387.52 Thousand USD | 21.94% |
| 2004 Q4 | 542.33 Thousand USD | -29.15% |
| 2004 Q1 | 317.79 Thousand USD | 0.78% |
| 2003 FY | 315.35 Thousand USD | 74.2% |
| 2003 Q3 | 164.45 Thousand USD | 40.12% |
| 2003 Q4 | 315.35 Thousand USD | 91.76% |
| 2003 Q2 | 117.36 Thousand USD | 100.76% |
| 2003 Q1 | 58.46 Thousand USD | -67.71% |
| 2002 FY | 181.02 Thousand USD | 0.0% |
| 2002 Q4 | 181.02 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| CannBioRx Life Sciences Corp. | 5.38 Million USD | -466.105% |
| China Jo-Jo Drugstores, Inc. | 80.76 Million USD | 62.239% |
| Harrow Health, Inc. 8.625% Senior Notes due 2026 | 241.75 Million USD | 87.385% |
| Harrow Health, Inc. 11.875% Senior Notes due 2027 | 241.75 Million USD | 87.385% |
| Leafly Holdings, Inc. | 34.29 Million USD | 11.069% |
| Leafly Holdings, Inc. | 34.29 Million USD | 11.069% |
| LifeMD, Inc. | 52.91 Million USD | 42.365% |
| LifeMD, Inc. | 52.91 Million USD | 42.365% |
| TRxADE HEALTH, Inc. | 11.99 Million USD | -154.344% |
| PetMed Express, Inc. | 78.36 Million USD | 61.082% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.956% |